National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Regorafenib (Stivarga®) indicated for the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.

Rapid Review

Commenced Completed Outcome
18/09/2014 06/10/2014 Full Pharmacoeconomic Evaluation Recommended.